Literature DB >> 20087887

Endogenous nociceptin/orphanin-FQ in the dorsal hippocampus facilitates despair-related behavior.

Celia Goeldner1, David Reiss, Brigitte L Kieffer, Abdel-Mouttalib Ouagazzal.   

Abstract

Nociceptin/orphanin-FQ (N/OFQ) peptide and its receptor (NOP: N/OFQ opioid peptide receptor) are highly expressed in the hippocampus, but their functional role remains poorly understood. We recently showed that hippocampal N/OFQ inhibits learning and memory abilities in mice. Here, we investigated whether the endogenous peptide also regulated emotional responses at the level of the hippocampus. Bilateral infusions of the selective NOP receptor antagonist, UFP-101 (1-3 nmol/side), into the dorsal hippocampus produced antidepressant-like effects in the mouse forced swim and tail suspension tests comparable with those obtained with the prototypical antidepressant, fluoxetine (10-30 mg/kg, intraperitoneal). In the light-dark test, neither UFP-101 (1-3 nmol/side) nor N/OFQ peptide (1-3 nmol/side) modified anxiety measures when injected at behaviorally active doses in the dorsal hippocampus. These findings show a clear dissociation in the involvement of hippocampal N/OFQ system in anxiety- and despair-related behaviors. We conclude that the dorsal hippocampus is a brain region in which there is an important N/OFQ modulation of mnemonic processes and adaptive emotional responses associated to despair states. Copyright 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20087887      PMCID: PMC4494786          DOI: 10.1002/hipo.20760

Source DB:  PubMed          Journal:  Hippocampus        ISSN: 1050-9631            Impact factor:   3.899


  36 in total

1.  OrphaninFQ: role in behavioral fear responses and vulnerability to stress?

Authors:  F Jenck; A M Ouagazzal; M Pauly-Evers; J L Moreau
Journal:  Mol Psychiatry       Date:  2000-11       Impact factor: 15.992

2.  Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test.

Authors:  John P Redrobe; Girolamo Calo'; Domenico Regoli; Rémi Quirion
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2001-12-20       Impact factor: 3.000

Review 3.  UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor.

Authors:  Girolamo Calo; Remo Guerrini; Anna Rizzi; Severo Salvadori; Melissa Burmeister; Daniel R Kapusta; David G Lambert; Domenico Regoli
Journal:  CNS Drug Rev       Date:  2005

4.  Involvement of the GABA/benzodiazepine receptor in the axiolytic-like effect of nociceptin/orphanin FQ.

Authors:  Hidemori Uchiyama; Taku Yamaguchi; Akihisa Toda; Takato Hiranita; Shigenori Watanabe; Reiko Eyanagi
Journal:  Eur J Pharmacol       Date:  2008-05-29       Impact factor: 4.432

5.  Neuronal mechanism of nociceptin-induced modulation of learning and memory: involvement of N-methyl-D-aspartate receptors.

Authors:  T Mamiya; K Yamada; Y Miyamoto; N König; Y Watanabe; Y Noda; T Nabeshima
Journal:  Mol Psychiatry       Date:  2003-08       Impact factor: 15.992

Review 6.  Orphanin FQ/nociceptin: a role in pain and analgesia, but so much more.

Authors:  T Darland; M M Heinricher; D K Grandy
Journal:  Trends Neurosci       Date:  1998-05       Impact factor: 13.837

7.  The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510).

Authors:  Geoffrey B Varty; Sherry X Lu; Cynthia A Morgan; Mary E Cohen-Williams; Robert A Hodgson; April Smith-Torhan; Hongtao Zhang; Ahmad B Fawzi; Michael P Graziano; Ginny D Ho; Julius Matasi; Deen Tulshian; Vicki L Coffin; Galen J Carey
Journal:  J Pharmacol Exp Ther       Date:  2008-05-20       Impact factor: 4.030

Review 8.  The effects of intra-cerebral drug infusions on animals' unconditioned fear reactions: a systematic review.

Authors:  Elif Engin; Dallas Treit
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-04-08       Impact factor: 5.067

9.  Nociceptin/orphanin FQ modulates spatial learning via ORL-1 receptors in the dorsal hippocampus of the rat.

Authors:  Johan Sandin; Sven O Ogren; Lars Terenius
Journal:  Brain Res       Date:  2004-02-06       Impact factor: 3.252

10.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

View more
  13 in total

1.  Activation of nociceptin/orphanin FQ peptide receptors disrupts visual but not auditory sensorimotor gating in BALB/cByJ mice: comparison to dopamine receptor agonists.

Authors:  Aurelia Ces; David Reiss; Ondine Walter; Jürgen Wichmann; Eric P Prinssen; Brigitte L Kieffer; Abdel-Mouttalib Ouagazzal
Journal:  Neuropsychopharmacology       Date:  2011-08-31       Impact factor: 7.853

2.  A history of chronic morphine exposure during adolescence increases despair-like behaviour and strain-dependently promotes sociability in abstinent adult mice.

Authors:  P E Lutz; D Reiss; A M Ouagazzal; B L Kieffer
Journal:  Behav Brain Res       Date:  2013-01-04       Impact factor: 3.332

3.  Further characterization of the prototypical nociceptin/orphanin FQ peptide receptor agonist Ro 64-6198 in rodent models of conflict anxiety and despair.

Authors:  Celia Goeldner; Will Spooren; Jürgen Wichmann; Eric P Prinssen
Journal:  Psychopharmacology (Berl)       Date:  2012-01-18       Impact factor: 4.530

4.  Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic-versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands.

Authors:  L Asth; C Ruzza; D Malfacini; I Medeiros; R Guerrini; N T Zaveri; E C Gavioli; G Calo'
Journal:  Neuropharmacology       Date:  2016-02-08       Impact factor: 5.250

5.  Orphanin FQ in the mediobasal hypothalamus facilitates sexual receptivity through the deactivation of medial preoptic nucleus mu-opioid receptors.

Authors:  Nayna M Sanathara; Justine Moraes; Shrey Kanjiya; Kevin Sinchak
Journal:  Horm Behav       Date:  2011-08-18       Impact factor: 3.587

Review 6.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

7.  Antidepressant activity of nociceptin/orphanin FQ receptor antagonists in the mouse learned helplessness.

Authors:  Victor A D Holanda; Iris U Medeiros; Laila Asth; Remo Guerrini; Girolamo Calo'; Elaine C Gavioli
Journal:  Psychopharmacology (Berl)       Date:  2016-04-30       Impact factor: 4.530

8.  Distinct mu, delta, and kappa opioid receptor mechanisms underlie low sociability and depressive-like behaviors during heroin abstinence.

Authors:  Pierre-Eric Lutz; Gulebru Ayranci; Paul Chu-Sin-Chung; Audrey Matifas; Pascale Koebel; Dominique Filliol; Katia Befort; Abdel-Mouttalib Ouagazzal; Brigitte L Kieffer
Journal:  Neuropsychopharmacology       Date:  2014-05-30       Impact factor: 7.853

9.  Decreased expression of nociceptin/orphanin FQ in the dorsal anterior cingulate cortex of suicides.

Authors:  Pierre-Eric Lutz; Yi Zhou; Aurélie Labbe; Naguib Mechawar; Gustavo Turecki
Journal:  Eur Neuropsychopharmacol       Date:  2015-08-24       Impact factor: 4.600

Review 10.  The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.

Authors:  Jeffrey M Witkin; Michael A Statnick; Linda M Rorick-Kehn; John E Pintar; Michael Ansonoff; Yanyun Chen; R Craig Tucker; Roberto Ciccocioppo
Journal:  Pharmacol Ther       Date:  2013-11-01       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.